	US 11,718,656 B2
	Inducible caspases and methods for use
Eric M. Ostertag, Lexington, KY (US); and Devon Shedlock, San Diego, CA (US)
Assigned to Poseida Therapeutics, Inc., San Diego, CA (US)
Filed by Poseida Therapeutics, Inc., San Diego, CA (US)
Filed on Jun. 2, 2022, as Appl. No. 17/830,773.
Application 17/830,773 is a division of application No. 16/339,710, granted, now 11,377,480, previously published as PCT/US2017/055661, filed on Oct. 6, 2017.
Claims priority of provisional application 62/405,184, filed on Oct. 6, 2016.
Prior Publication US 2023/0002469 A1, Jan. 5, 2023
Int. Cl. C12N 15/52 (2006.01); C07K 14/705 (2006.01); C07K 14/47 (2006.01); A61P 37/00 (2006.01); A61P 31/00 (2006.01); A61P 3/00 (2006.01); A61P 17/02 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61K 35/17 (2015.01); C12N 5/0783 (2010.01); C12N 9/50 (2006.01)

CPC C07K 14/705 (2013.01) [A61K 35/17 (2013.01); A61P 3/00 (2018.01); A61P 17/02 (2018.01); A61P 29/00 (2018.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); A61P 37/00 (2018.01); C07K 14/47 (2013.01); C07K 14/4747 (2013.01); C12N 5/0636 (2013.01); C12N 9/50 (2013.01); C12N 15/52 (2013.01); C12Y 304/22036 (2013.01)]

10 Claims

1. A polynucleotide comprising the nucleic acid sequence of SEQ ID NO: 10.